Axar.az
UP

Axar.Az Logo

Johnson & Johnson's one-dose vaccine closes in on U.S. approval

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

Johnson & Johnson’s one-dose COVID-19 vaccine appeared safe and effective in trials, the U.S. Food and Drug Administration said Wednesday, paving the way for its approval for emergency use as soon as this week.

Axar.az reports that the vaccine was 66% effective at preventing moderate to severe COVID-19 in a 44,000 person global trial, the FDA said in documents ahead of a Friday meeting of independent experts who will advise the agency on the emergency authorization.

New data provided by J&J to the FDA showed the vaccine was 64% effective at stopping moderate to severe cases of COVID-19 after 28 days in thousands of trial participants in South Africa where a worrying new variant has swept across the country.

Overall, the vaccine was 100% effective at stopping hospitalization 28 days after vaccination, compared with 85% at 14 days, and there were no COVID-19 deaths among those who received the shot rather than a placebo.

Date
2021.02.25 / 09:51
Author
Axar.az
Comments
See also

WHO views world’s epidemiological situation as alarming

Global COVID-19 deaths surpass 3 mln

WHO: COVID cases, deaths rising at worrying rates

4 deaths after taking Russian Sputnik V vaccine

Coronavirus vaccine is prepared in spray form

Brazil finds new virus variant combining 18 mutations

WHO records over 517,000 new daily cases of COVID-19

WHO statement on "vaccination passport"

100M Americans received at least one vaccine dose

Yemen gets first COVID-19 vaccines

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla